Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
β Scribed by Shinji Uchida; Tadaaki Taniguchi; Takafumi Shimizu; Taro Kakikawa; Kotoba Okuyama; Masahiko Okaniwa; Hironori Arizono; Koichi Nagata; Arthur C. Santora; Masataka Shiraki; Masao Fukunaga; Tatsushi Tomomitsu; Yasuo Ohashi; Toshitaka Nakamura
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 721 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0914-8779
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a onceβyearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi
## Abstract ## Objective To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA). ## Methods Four hundred twenty RA patients were randomized to receive, in a blinded manner, the stu